- 01More than a thousand cancer vaccine trials failed before this one, and most researchers had quietly given up on the idea that the immune system could be taught to fight a patient's specific tumor.
- 02The Phase 3 trial enrolled 1,137 patients with high-risk melanoma who had already undergone surgery, which is exactly the setting where preventing recurrence matters most.
- 03Moderna builds a completely different vaccine for every single patient, which means no two doses that have ever been manufactured are the same medicine.
- 04Each vaccine encodes up to 34 mutations pulled directly from that patient's tumor, chosen because they are the ones the immune system is most likely to recognize and attack.
- 05The combination cut recurrence risk by 49% and distant metastasis risk by 59% compared to Keytruda alone, which is already considered the best drug available for this cancer.
- 06Keytruda has never been beaten in this setting before, and the fact that something outperformed it in a randomized Phase 3 trial is the reason the entire oncology field took notice.
- 07From the moment a surgeon removes the tumor to the day a patient receives their personalized dose, Moderna has compressed the entire manufacturing process to roughly 42 days.
- 08The stock moved 177% in a single session, the largest one-day percentage gain in the S&P 500 in 25 years, adding roughly $38 billion in market cap before the close.
- 09Moderna is now running studies in lung, kidney, bladder, pancreatic and gastric cancers, which together represent a far larger patient population than melanoma ever could.
- 10The same mRNA platform that was originally built for infectious disease is now being tested against autoimmune conditions, which suggests the technology has a much broader surface area than most people currently price in.
How Moderna Is Building a Personalized Cancer Vaccine for Every Patient
"The combination cut recurrence risk by 49% compared to Keytruda alone, which is already considered the best drug available for this cancer." — Stéphane Bancel, CEO Moderna